Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia: a case series

Autor: Rob Pieters, Erin H. Breese, Luciano Dalla-Pozza, Nicole Bodmer, Kjeld Schmiegelow, Christian M. Zwaan, Adriana Thano, Raoull Hoogendijk, Fanny Rialland, Christophe F Chantrain, Audrey Contet, Erica Brivio, Inna V. Markova, Krisztián Miklós Kállay, Motohiro Kato, Tanja A. Gruber, Sarah Elitzur, Chi Kong Li
Přispěvatelé: Pediatrics, University of Zurich, Zwaan, Christian Michel
Rok vydání: 2021
Předmět:
Zdroj: British Journal of Haematology, 193(6), 1172-1177. Wiley-Blackwell Publishing Ltd
ISSN: 1365-2141
0007-1048
Popis: No data on inotuzumab ozogamicin (InO) in infant acute lymphoblastic leukaemia (ALL) have been published to date. We collected data internationally on infants/young children (+ blasts was 72% (range 40–100%, n = 9). The median dose in the first course was 1.74 mg/m2 (fractionated). Seven patients (47%) achieved complete remission; one additional minimal residual disease (MRD)-positive patient became MRD-negative. Six-month overall survival was 47% (95% confidence interval [CI] 27–80%). Two patients developed veno-occlusive disease after transplant. Further evaluation of InO in this subgroup of ALL is justified.
Databáze: OpenAIRE